SOCRA CCRP Practice Exam (Sample)

Study Guide

Everything you need from our exam experts!

Questions

1. What type of findings must be reported in narrative format in IND safety reports for drug studies?

A. Findings from clinical studies only

B. Findings from animal studies only

C. Overall findings or pooled analyses from various types of studies

D. Only findings related to adverse drug reactions

2. What do pharmacokinetic studies (PK) primarily focus on?

A. The legal aspects of drug distribution

B. What the body does to the drug

C. What the drug does to the body

D. How the drug is advertised

3. What FDA regulations govern UADE reporting?

A. 21 CFR 101

B. 21 CFR 812

C. 42 CFR 483

D. 30 CFR 250

4. How many activities must IRBs maintain documentation of?

A. 5

B. 7

C. 4

D. 10

5. What does Phase IIIb of clinical trials focus on?

A. Initial drug discovery

B. Efficacy in large patient groups

C. Safety in real-world settings

D. Additional disease indications or marketing claims

6. Which studies require submission of an IDE application?

- **A. All clinical device studies**
- **B. Device studies not intended for human use**
- **C. Studies supporting premarket approval and some 510(k) notifications**
- **D. In-vitro diagnostics studies only**

7. What do FDA regulations mandate for sponsors regarding the Investigator's Brochure?

- **A. Provide it only at the end of the investigation**
- **B. Provide at the beginning and keep investigators informed of new AEs**
- **C. They do not need to provide it**
- **D. Inform investigators about AEs only**

8. What is the regulatory process if a device meets even one criterion for exemption?

- **A. IRB review and approval, no FDA notification**
- **B. FDA review and approval, then IRB**
- **C. Direct FDA approval**
- **D. Both FDA and IRB review concurrently**

9. What must research involving children with greater than minimal risk and the prospect of direct benefit meet to be IRB-approved?

- **A. Only risk is justified by anticipated benefits**
- **B. Benefits are provided to all participants**
- **C. Risk is related to the benefit and is at least as favorable as any alternative**
- **D. Parental consent is not required**

10. What must the relationship of risk to benefit be for research in kids with more than minimal risk and prospect of benefit?

- **A. Minimal**
- **B. High risk, no need for direct benefit**
- **C. At least as favorable as any alternative**
- **D. Decided by the parents**

Answers

1. C
2. B
3. B
4. B
5. D
6. C
7. B
8. A
9. C
10. C

Explanations

1. What type of findings must be reported in narrative format in IND safety reports for drug studies?

A. Findings from clinical studies only

B. Findings from animal studies only

C. Overall findings or pooled analyses from various types of studies

D. Only findings related to adverse drug reactions

Narrative format in IND safety reports for drug studies requires an overall summary of findings from various types of studies, such as clinical and animal studies. Option A is incorrect because it only includes findings from clinical studies, which may not capture the full picture of drug safety. Option B is incorrect because it only includes findings from animal studies, which also may not accurately represent the safety of the drug in humans. Option D is incorrect because it only includes findings related to adverse drug reactions, which is important but not the only type of finding that needs to be included in a narrative format. Option C is the best answer as it encompasses all relevant findings from different types of studies to provide a comprehensive report on the safety of the drug.

2. What do pharmacokinetic studies (PK) primarily focus on?

A. The legal aspects of drug distribution

B. What the body does to the drug

C. What the drug does to the body

D. How the drug is advertised

Pharmacokinetic studies (PK) primarily focus on what the body does to the drug. This involves studying how drugs are absorbed, distributed, metabolized, and eliminated by the body. It does not focus on the legal aspects of drug distribution (A), as this falls under pharmacology and the regulation of drugs. It also does not focus on what the drug does to the body (C), as this is studied in pharmacodynamics. And it is definitely not about how the drug is advertised (D), as that falls under marketing and not scientific research.

3. What FDA regulations govern UADE reporting?

A. 21 CFR 101

B. 21 CFR 812

C. 42 CFR 483

D. 30 CFR 250

The correct answer is B 21 CFR 812. The UADE reporting regulations for medical devices are governed by the Food and Drug Administration (FDA) under 21 CFR 812. This specific section of the Code of Federal Regulations is dedicated to the requirements for Investigational Device Exemptions, including the reporting of Unanticipated Adverse Device Effects (UADEs). Therefore, options A, C, and D are incorrect because they refer to different sections of the Code of Federal Regulations that do not pertain to medical device reporting. Option A (21 CFR 101) relates to labeling and nutrient content claims for food products, option C (42 CFR 483) pertains to long-term care facilities, and option D (30 CFR 250) deals with offshore drilling and worker safety.

4. How many activities must IRBs maintain documentation of?

A. 5

B. 7

C. 4

D. 10

IRBs, or Institutional Review Boards, are responsible for reviewing and approving research involving human subjects. This includes maintaining documentation of all activities related to the review and approval process. This documentation is essential for ensuring that the research is ethical and compliant with regulations. In order to maintain thorough documentation, it is necessary for IRBs to keep track of all aspects of the review process, including any revisions or updates. Option A, 5 activities, may not provide enough detail to accurately document the process. Option C, 4 activities, may not cover all necessary components of the review. Option D, 10 activities, may include unnecessary details that are not relevant to the review. Therefore, option B, 7 activities, appears to be the most appropriate and comprehensive choice.

5. What does Phase IIIb of clinical trials focus on?

A. Initial drug discovery

B. Efficacy in large patient groups

C. Safety in real-world settings

D. Additional disease indications or marketing claims

Phase IIIb clinical trials typically focus on gathering additional evidence related to the efficacy and safety of a drug that has already demonstrated favorable results in Phase III trials, particularly in larger patient groups. This phase is crucial for providing further insights into the drug's effectiveness, side effects, and optimal use before it receives full marketing approval. Specifically, Phase IIIb studies often investigate additional disease indications or explore marketing claims that were not thoroughly assessed during the earlier phases. This can include evaluating the drug's performance in a wider population, including various demographic groups or in combination with other therapies, thus allowing for a more comprehensive understanding of its therapeutic benefits and potential limitations. Because these trials build upon the established foundation from earlier phases, they play a vital role in confirming the drug's value in the real-world setting, addressing further nuances of treatment protocols, or submitting information to support expanded indications. This not only assists healthcare providers in making informed decisions but also enables regulatory agencies to fully understand the scope and impact of the medication within broader clinical use.

6. Which studies require submission of an IDE application?

A. All clinical device studies

B. Device studies not intended for human use

C. Studies supporting premarket approval and some 510(k) notifications

D. In-vitro diagnostics studies only

Studies requiring submission of an IDE application include those that support premarket approval and some 510(k) notifications. Option A is incorrect because not all clinical device studies require an IDE application. Option B is incorrect because even if a device is not intended for human use, if it supports premarket approval or a 510(k) notification, an IDE application is still required. And option D is incorrect because in-vitro diagnostics studies do not require an IDE application unless they also support premarket approval or a 510(k) notification.

7. What do FDA regulations mandate for sponsors regarding the Investigator's Brochure?

A. Provide it only at the end of the investigation

B. Provide at the beginning and keep investigators informed of new AEs

C. They do not need to provide it

D. Inform investigators about AEs only

The FDA regulations mandate that sponsors provide the Investigator's Brochure at the beginning of an investigation and keep investigators informed of any new adverse events. This is to ensure that investigators have the most up-to-date information on the investigational product in order to make informed decisions about the safety and effectiveness of the product. Providing the brochure only at the end of the investigation (option A) would not be sufficient, as it would not allow investigators to make any necessary adjustments during the trial. Option C is incorrect, as the regulations do require sponsors to provide the Investigator's Brochure. Option D is also incorrect, as the regulations not only require informing investigators about adverse events, but also providing the full Investigator's Brochure. Therefore, option B is the correct and complete answer.

8. What is the regulatory process if a device meets even one criterion for exemption?

A. IRB review and approval, no FDA notification

B. FDA review and approval, then IRB

C. Direct FDA approval

D. Both FDA and IRB review concurrently

If a device meets even one criterion for exemption, it means that the device does not need to go through the FDA review and approval process. Instead, the device can go through IRB review and approval. Option B is incorrect because it suggests that the device would still need to go through FDA review and approval before going through IRB review. Option C is incorrect because it suggests that the device would only need FDA approval and not IRB approval, which is not the case for exemption. Option D is incorrect because it suggests that both the FDA and IRB would need to review the device concurrently, which is not necessary for exemption. In summary, option A is the correct answer because it accurately explains the regulatory process for devices that meet even one criterion for exemption.

9. What must research involving children with greater than minimal risk and the prospect of direct benefit meet to be IRB-approved?

A. Only risk is justified by anticipated benefits

B. Benefits are provided to all participants

C. Risk is related to the benefit and is at least as favorable as any alternative

D. Parental consent is not required

One option that is incorrect is A, which only requires that the risks are justified by anticipated benefits, but it does not specify that the risks must be at least as favorable as any alternative. Another incorrect option is B, which states that benefits must be provided to all participants, but it does not mention anything about risks or how they relate to the benefits. D is also incorrect because parental consent is always required for research involving children, regardless of the level of risk or potential benefit. C is the correct answer because it specifies that the risks must be related to the benefits and must be at least as favorable as any alternative. This ensures that the potential benefits outweigh the potential risks and that the research is ethically sound in regards to children.

10. What must the relationship of risk to benefit be for research in kids with more than minimal risk and prospect of benefit?

A. Minimal

B. High risk, no need for direct benefit

C. At least as favorable as any alternative

D. Decided by the parents

The relationship of risk to benefit must be at least as favorable as any alternative for research involving children with more than minimal risk and prospect of benefit. This means that the benefits of the research must outweigh the risks, and the risks must not be worse than any available alternative. This is important for ensuring the well-being and safety of the child participants. Options A and B are incorrect because they do not consider the need for balancing risk and benefit. Option D is incorrect because the decision should not be solely left to the parents, as the well-being of the child is the primary concern in research involving minors.